Gilead shares have added about 19.4% since the beginning of the year versus the S&P 500's gain of 7.9%. What's Next for Gilead? While Gilead has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also ho ...

In the latest trading session, Gilead Sciences (GILD) closed at $109.06, marking a -2.7% move from the previous day. This change lagged the S&P 500's daily loss of 0.4%. Meanwhile, the Dow lost 0.98%, and the Nasdaq, a tech-heavy index, added 0.18%. Coming into today, shares of the HIV and hepatitis C drugmaker had gained 1.14% in the past month. In that same time, the Medical sector lost 1.56%, while the S&P 500 gained 4.97%. Investors should also pay attention to any latest changes in analyst estimates fo ...